Oral Thrush Market Research Report- Global Forecast till 2023

Oral Thrush Market Research Report- Global Forecast till 2023

ID: MRFR/HC/3008-HCRR | April, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports

Oral Thrush Market Information: By Type (Pseudomembranous, Erythematous, Hyperplastic, others), Diagnosis (Examination, Biopsy, Endoscopy, others), Treatment (Anti-Fungal, Immune-Modulators), End User (Hospitals & Clinics) - Global Forecast Till 2023



Market Synopsis of Global Oral Thrush Market
Market Scenario
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand  other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of  HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.


Apart from common symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.


Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high  carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.


Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.


The global oral thrush market is expected to reach USD 9.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.



Research Methodology

Oral Thrush Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


 


Intended Audience



  • Global oral thrush treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities




Figure 1          Global oral thrush market by types, 2016 (%)

Oral Thrush Market-


Segments:
The global oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.


Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.


Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.


Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.


Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.



Regional Analysis
The Americas accounts for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new products in the US drives the oral thrush market. Also, concentration of major healthcare companies in the developed countries of this region coupled with the larger market for oral hygiene products is adding fuel to the market growth. Moreover, the US expend high on the healthcare, which accounts for 16% of GDP also cruises the sale of oral thrush treatment.


Europe is the second largest market in the world due to high income and strong healthcare penetration. European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. Furthermore, the high influence of media and the rise in the awareness regarding oral hygiene coupled with the high per capita income of the population drive the European oral thrush market.


Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs during the forecast period. South East Asian countries such as Vietnam, Thailand, and Malaysia are projected to contribute highly to the market growth.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for will be Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However,  Africa has the highest unmet needs in the world and cost-effective products will be the key to dominate the African market. First comer will take advantage and establish the dominance in the African market, which will be difficult to overcome by any new player due to the smaller market size and market value of the African market for oral thrush.



Key Players in the Global Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Oral Thrush Market, by Types

6.1 Introduction

6.2 Pseudomembranous

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Erythematous

6.3.1 Market Estimates & Forecast, 2017-2023

6.4 Hyperplastic

6.4.1 Market Estimates & Forecast, 2017-2023

6.5 Others

6.5.1 Market Estimates & Forecast, 2017-2023

7. Global Oral Thrush Market, by Diagnosis

7.1 Introduction

7.2 Examination

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 Biopsy

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Endoscopy

7.4.1 Market Estimates & Forecast, 2017-2023

7.5 Others

7.5.1 Market Estimates & Forecast, 2017-2023

8. Global Oral Thrush Market, by Treatment

8.1 Introduction

8.2 Anti-Fungal

8.2.1 Market Estimates & Forecast, 2017-2023

8.3 Immune-Modulators

8.3.1 Market Estimates & Forecast, 2017-2023

8.4 Others

8.4.1 Market Estimates & Forecast, 2017-2023

9. Global Oral Thrush Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2017-2023

9.3 Academic and Research Institutes

9.3.1 Market Estimates & Forecast, 2017-2023

9.3 Others

9.3.1 Market Estimates & Forecast, 2017-2023

10. Global Oral Thrush Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Bayer AG

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key Developments

12.2 Teva Pharmaceuticals

12.2.1 Overview

12.2.2 Product Overview

12.2.3 Financials

12.2.4 Key Developments

12.3 Stellar Pharma

12.3.1 Overview

12.3.2 Product Overview

12.3.3 Financials

12.3.4 Key Development

12.4 Pfizer Inc.

12.4.1 Overview

12.4.2 Product Overview

12.4.3 Financials

12.4.3 Key Development

12.5 Wockhardt Ltd.

12.5.1 Overview

12.5.2 Product Overview

12.5.3 Financials

12.5.4 Key Development

12.6 Ranbaxy Laboratories Limited

12.6.1 Overview

12.6.2 Product Overview

12.6.3 Financials

12.6.4 Key Development

12.7 Bristol Laboratories

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Development

12.8 Glenmark Pharmaceuticals

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Development

12.9 GlaxoSmithKline Plc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Development

12.10 Others

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Development

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix





List of Tables



TABLE 1 GLOBAL ORAL THRUSH MARKET, BY TYPE, 2017-2023 (USD MILLION)

TABLE 2 PHYSICAL EXAMINATION FOR ORAL THRUSH MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 3 PSEUDOMEMBRANOUS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD

MILLION)

TABLE 4 ERYTHEMATOUS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD

MILLION)

TABLE 5 HYPERPLASTIC FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 6 OTHERS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 7 GLOBAL ORAL THRUSH MARKET, BY DIAGNOSIS, 2017-2023 (USD MILLION)

TABLE 8 EXAMINATION FOR ORAL THRUSH MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 9 BIOPSY FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 10 ENDOSCOPY FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 11 OTHERS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 12 GLOBAL ORAL THRUSH MARKET, BY TREATMENT, 2017-2023 (USD MILLION)

TABLE 13 ANTI-FUNGAL FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 14 IMMUNE-MODULATORS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD

MILLION)

TABLE 15 OTHERS FOR ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 16 GLOBAL ORAL THRUSH MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 17 NORTH AMERICA ORAL THRUSH MARKET, BY COUNTRY 2017-2023 (USD MILLION)

TABLE 18 NORTH AMERICA ORAL THRUSH MARKET, BY TYPE 2017-2023 (USD MILLION)

TABLE 19 NORTH AMERICA ORAL THRUSH MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 20 NORTH AMERICA ORAL THRUSH MARKET, BY TREATMENT 2017-2023 (USD

MILLION)

TABLE 21 NORTH AMERICA ORAL THRUSH MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 22 NORTH AMERICA ORAL THRUSH MARKET BY REGION 2017-2023 (USD MILLION

TABLE 23 EUROPE ORAL THRUSH MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 24 EUROPE ORAL THRUSH MARKET, BY TYPE 2017-2023 (USD MILLION)

TABLE 25 EUROPE ORAL THRUSH MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 26 EUROPE ORAL THRUSH MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 27 EUROPE ORAL THRUSH MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 28 EUROPE ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 29 ASIA PACIFIC ORAL THRUSH MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 30 ASIA PACIFIC ORAL THRUSH MARKET, BY TYPE 2017-2023 (USD MILLION)

TABLE 31 ASIA PACIFIC ORAL THRUSH MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 32 ASIA PACIFIC ORAL THRUSH MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 33 ASIA PACIFIC ORAL THRUSH MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 34 ASIA PACIFIC ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA ORAL THRUSH MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY TYPE 2017-2023 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY REGION 2017-2023 (USD MILLION)





List of Figures



FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR GLOBAL ORAL THRUSH MARKET

FIGURE 3 GLOBAL ORAL THRUSH MAKRET, BY SEGMENT, 2016

FIGURE 4 GLOBAL ORAL THRUSH SUCCESS MARKET, BY REGION

FIGURE 5 GLOBAL ORAL THRUSH MARKET SHARE, BY TYPE 2016

FIGURE 6 GLOBAL ORAL THRUSH MARKET SHARE, BY DIAGNOSIS 2016

FIGURE 7 GLOBAL ORAL THRUSH MARKET SHARE, BY TREATMENT, 2016

FIGURE 8 GLOBAL ORAL THRUSH MARKET SHARE, BY END USER, 2016

FIGURE 9 GLOBAL ORAL THRUSH MARKET SHARE, 2016

FIGURE 10 GLOBAL ORAL THRUSH MARKET SHARE, BY REGION, 2016

FIGURE 11 NORTH AMERICA ORAL THRUSH MARKET SHARE, BY COUNTRY, 2016

FIGURE 12 EUROPE ORAL THRUSH MARKET SHARE, BY COUNTRY, 2016

FIGURE 13 ASIA PACIFIC ORAL THRUSH MARKET SHARE, BY COUNTRY, 2016

FIGURE 14 MIDDLE EAST & AFRICA ORAL THRUSH MARKET, BY REGION, 2016

FIGURE 15 GLOBAL ORAL THRUSH MARKET: COMPANY SHARE ANALYSIS, 2016 (%)

FIGURE 16 PFIZER INC.: KEY FINANCIALS

FIGURE 17 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 18 PFIZER INC.: GEOGRAPHICAL REVENUE

FIGURE 19 BAYER AG: KEY FINANCIALS

FIGURE 20 BAYER AG: SEGMENTAL REVENUE

FIGURE 21 BAYER AG: GEOGRAPHICAL REVENUE

FIGURE 22 GLENMARK PHARMACEUTICALS: KEY FINANCIALS

FIGURE 23 GLENMARK PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 24 GLENMARK PHARMACEUTICALS: GEOGRAPHICAL REVENUE

FIGURE 25 RANBAXY LABORATORIES LIMITED: KEY FINANCIALS

FIGURE 26 RANBAXY LABORATORIES LIMITED: SEGMENTAL REVENUE

FIGURE 27 RANBAXY LABORATORIES LIMITED: GEOGRAPHICAL REVENUE

FIGURE 28 GLAXOSMITHKLINE: FINANCIAL REVENUE

FIGURE 29 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 30 GLAXOSMITHKLINE: GEOGRPAHICAL REVENUE

FIGURE 31 WOCKHARDT LTD.: FINANCIAL REVENUE

FIGURE 32 WOCKHARDT LTD.: SEGMENTAL REVENUE

FIGURE 33 WOCKHARDT LTD.: GEOGRPAHICAL REVENUE